At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
Biotronik Biomonitor 3 implant of device +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors
In Brief
A clinical study evaluating Biotronik Biomonitor 3 implant of device and Biotronik Biomonitor 3 explant of device for TTR Cardiac Amyloidosis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Researchers are gathering information to see if using an FDA approved implantable device can help with monitoring of your heart arrhythmias.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTTR Cardiac Amyloidosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionMar 2023
TodayJul 2026
First PostedJun 9, 2020
Enrollment StartOct 7, 2020
Primary CompletionMar 22, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.1 years ago
Interventions
Biotronik Biomonitor 3 implant of devicedevice
The Biotronik Biomonitor 3 device will be implanted by the research team physician.
Biotronik Biomonitor 3 explant of devicedevice
The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.